Pharmaceutical majors are committing extensive capital expenditures to expand sterile fill-finish capacity for GLP-1 receptor agonists. The expansion comes as clinical trials validate secondary indications for cardiovascular health and kidney disease risk reduction.
Manufacturing Scale and Cost Dynamics
Active pharmaceutical ingredient synthesis bottlenecks are easing, yet high-volume injector pen manufacturing remains constrained. Analysts forecast that scaling production will lower unit costs by 2026, widening payer coverage across both public healthcare systems and private insurers.